Story thread · 2 reports / 2 sources
Pfizer shares ADC rights with Medicus; RevMed updates lung cancer data
endpts.com · 11d
Plus, news about Novartis. 🤝 Pfizer turns over ADC: The New York pharma is giving Medicus Pharma co-development rights to a CD228-targeted antibody-drug conjugate known as PF-08046031, a Seagen-derived asset that it ...
First report: Pfizer, Medicus ink licensing deal worth up to $1B for antibody drug conjugate — seekingalpha.com, 11d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.